Larynx Cancer disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

MCID: LRY044 MIFTS: 55	Larynx Cancer Categories: Cancer diseases, Oral diseases, Rare diseases, Respiratory diseases	Data Licensing For inquiries, contact: [email protected]
Genes Tissues Related diseases Publications Drugs Expand all tables

Sources

Aliases & Classifications for Larynx Cancer

MalaCards integrated aliases for Larynx Cancer:

Name: Larynx Cancer ¹¹ ¹⁴

Laryngeal Carcinoma ¹¹ ¹⁹ ⁷⁵ ⁵³ ¹⁴

Laryngeal Cancer ¹⁹ ⁵³ ⁷⁵

Malignant Neoplasm of Larynx ⁷¹ ³¹

Carcinoma of Larynx ¹¹ ⁷¹

Laryngeal Neoplasm ¹⁶ ⁷¹

Laryngeal Neoplasms ⁴³

Cancer, Laryngeal ³⁸

Cancer of Larynx ¹¹

Classifications:

MalaCards categories:
Global: Rare diseases Cancer diseases
Anatomical: Respiratory diseases Oral diseases

See all MalaCards categories (disease lists)

ICD10: ³¹

Neoplasms

Malignant neoplasms of respiratory and intrathoracic organs

Malignant neoplasm of larynx

Malignant neoplasm: Larynx, unspecified

External Ids:

Disease Ontology ¹¹ DOID:2596 DOID:2600

ICD9CM ³⁴ 161

MeSH ⁴³ D007822

NCIt ⁴⁹ C4855 C7484

SNOMED-CT ⁶⁸ 154480006 93859007

ICD10 ³¹ C32 C32.9

EFO ¹⁶ EFO_0003817

UMLS ⁷¹ C0007107 C0023055 C0595989

Sources

Summaries for Larynx Cancer

Disease Ontology ¹¹ Larynx cancer: A respiratory system cancer that is located in the larynx.

Laryngeal carcinoma: A larynx cancer that has material basis in epithelial cells.

MalaCards based summary: Larynx Cancer, also known as laryngeal carcinoma, is related to laryngeal benign neoplasm and laryngeal squamous cell carcinoma. An important gene associated with Larynx Cancer is MIR21 (MicroRNA 21), and among its related pathways/superpathways are Nuclear receptors meta-pathway and Malignant pleural mesothelioma. The drugs Nicotinamide and Docetaxel have been mentioned in the context of this disorder. Affiliated tissues include larynx, lymph node and lung, and related phenotype is neoplasm.

GARD: ¹⁹ A carcinoma of the larynx.

Wikipedia: ⁷⁵ Laryngeal cancers are mostly squamous-cell carcinomas, reflecting their origin from the epithelium of... more...

Sources

Related Diseases for Larynx Cancer

Diseases in the Larynx Cancer family:

Larynx Carcinoma in Situ

Diseases related to Larynx Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 653)

#	Related Disease	Score	Top Affiliating Genes
1	laryngeal benign neoplasm	31.7	TP53 MIR106B EGFR CCND1
2	laryngeal squamous cell carcinoma	30.9	TP53 TERT NME1 MKI67 MIR21 MIR139
3	keratoacanthoma	30.8	TP53 MKI67 EGFR BCL2
4	squamous cell carcinoma	30.8	TP53 TERT NME1 MKI67 GSTP1 EGFR
5	small cell cancer of the lung	30.6	TP53 MIR21 EGFR BCL2
6	suppressor of tumorigenicity 3	30.6	TP53 BCL2
7	adenoid cystic carcinoma	30.5	TP53 MKI67 EGFR CCND1 BCL2
8	hypopharynx cancer	30.5	TP53 NME1 MIR143 EGFR CCND1 BCL2
9	papilloma	30.5	TP53 GSTP1 EGFR CCND1 BCL2
10	b-cell lymphoma	30.4	TP53 MKI67 GSTP1 CCND1 BCL2
11	head and neck cancer	30.4	TP53 MIR486-1 MIR31 MIR21 MIR145 MIR143
12	lip and oral cavity cancer	30.4	TP53 MIR31 MIR21 GSTM3 GSTM1 EGFR
13	gastroesophageal reflux	30.4	TP53 TERT MKI67 EGFR CCND1 BCL2
14	colon adenocarcinoma	30.3	TP53 MKI67 EGFR CCND1 BCL2
15	pharynx cancer	30.3	MIR486-1 MIR31 MIR21 MIR148A MIR145 MIR143
16	skin carcinoma	30.3	TP53 MIR31 MIR21 EGFR CCND1 BCL2
17	keratosis	30.3	TP53 EGFR BCL2
18	inverted papilloma	30.3	TP53 MKI67 CCND1
19	adenoma	30.3	TP53 MKI67 CCND1 BCL2
20	skin squamous cell carcinoma	30.3	TP53 MIR21 EGFR CCND1
21	breast adenocarcinoma	30.2	TP53 EGFR CCND1 BCL2
22	acquired immunodeficiency syndrome	30.2	TP53 GSTM1 CCND1 BCL2
23	lung benign neoplasm	30.2	TP53 TERT GSTP1 EGFR
24	spinal cord disease	30.2	TP53 TERT MIR139 MIR106B EGFR
25	laryngeal disease	30.2	MIR486-1 MIR31 MIR21 MIR148A MIR145 MIR143
26	large cell carcinoma	30.2	TP53 MIR31 MIR145 EGFR
27	myocardial infarction	30.2	TP53 MIR486-1 MIR21 MIR145 MIR143 MIR139
28	cervical adenocarcinoma	30.2	TP53 NME1 MKI67
29	cervical cancer	30.1	TP53 TERT NME1 MIR31 MIR21 MIR143
30	esophagus adenocarcinoma	30.1	TP53 MIR21 MIR145 MIR143 EGFR CCND1
31	lung squamous cell carcinoma	30.1	TP53 MIR145 MIR139 EGFR
32	oral cavity cancer	30.1	MIR486-1 MIR31 MIR21 MIR145 MIR143 MIR139
33	leiomyosarcoma	30.1	TP53 CCND1 BCL2
34	oropharynx cancer	30.1	TP53 MIR486-1 MIR21 MIR139 EGFR CCND1
35	kidney cancer	30.1	TP53 MIR21 MIR145 MIR106B GSTP1 EGFR
36	pancreatic adenocarcinoma	30.1	TP53 EGFR CCND1 BCL2
37	wilms tumor 1	30.1	TP53 TERT EGFR CCND1 BCL2
38	lynch syndrome	30.1	TP53 TERT MIR31 MIR139 EGFR CCND1
39	thyroid gland anaplastic carcinoma	30.1	TP53 TERT MIR145 EGFR CCND1 BCL2
40	cholangiocarcinoma	30.1	TP53 TERT MIR21 MIR148A EGFR CCND1
41	tongue carcinoma	30.1	TP53 TERT MIR31 MIR21 MIR143 MIR139
42	myeloma, multiple	30.1	TP53 MIR21 MIR145 MIR106B CCND1 BCL2
43	transitional cell carcinoma	30.1	TP53 NME1 MKI67 GSTP1 GSTM1 EGFR
44	basal cell carcinoma	30.1	TP53 MKI67 GSTP1 GSTM3 GSTM1 EGFR
45	colonic benign neoplasm	30.1	TP53 MIR21 MIR145 MIR143 EGFR CCND1
46	rhabdomyosarcoma	30.0	TP53 TERT EGFR CCND1 BCL2
47	human papillomavirus infectious disease	30.0	TP53 TERT MIR486-1 MIR31 MIR21 MIR139
48	glioblastoma	30.0	TP53 TERT MIR486-1 MIR21 EGFR CCND1
49	nasopharyngeal carcinoma	30.0	TP53 TERT NME1 MIR486-1 MIR31 MIR21
50	peripheral nervous system disease	30.0	TP53 TERT MIR486-1 MIR31 MIR21 MIR145

Comorbidity relations with Larynx Cancer via Phenotypic Disease Network (PDN):

Bronchitis	Deficiency Anemia
Pharynx Cancer	Protein-Energy Malnutrition
Respiratory Failure	Supraglottis Cancer
Swallowing Disorders

Graphical network of the top 20 diseases related to Larynx Cancer:

Sources

Symptoms & Phenotypes for Larynx Cancer

MGI Mouse Phenotypes related to Larynx Cancer:

⁴⁵

#	Description	MGI Source Accession	Score	Top Affiliating Genes
1	neoplasm	MP:0002006	9.32	BCL2 CCND1 EGFR GSTP1 MIR139 MIR31

Sources

Drugs & Therapeutics for Larynx Cancer

Drugs for Larynx Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 168)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Nicotinamide

Approved, Investigational

Phase 3

98-92-0

936

Docetaxel

Approved, Investigational

Phase 3

114977-28-5

148124

Cefazolin

Approved

Phase 3

25953-19-9

33255

Fluorouracil

Approved

Phase 3

51-21-8

3385

Hydroxyurea

Approved

Phase 3

127-07-1

3657

Ethanol

Approved

Phase 3

64-17-5

702

Atezolizumab

Approved, Investigational

Phase 2, Phase 3

1380723-44-3

Bevacizumab

Approved, Investigational

Phase 2, Phase 3

216974-75-3

135329020

Sucralfate

Approved

Phase 3

54182-58-0

Durvalumab

Approved, Investigational

Phase 2, Phase 3

1428935-60-7

Niacin

Approved, Investigational, Nutraceutical

Phase 3

59-67-6

938

Folic acid

Approved, Nutraceutical, Vet_approved

Phase 3

59-30-3

6037

Vitamins

Phase 3

Vitamin B3

Phase 3

Nicotinic Acids

Phase 3

Antimetabolites

Phase 3

Folate

Phase 3

Vitamin B9

Phase 3

Vasodilator Agents

Phase 3

Vitamin B Complex

Phase 3

Hypolipidemic Agents

Phase 3

Lipid Regulating Agents

Phase 3

Endothelial Growth Factors

Phase 2, Phase 3

Aloe

Phase 3

Anti-Ulcer Agents

Phase 3

Antacids

Phase 3

Immunoglobulin G

Phase 2, Phase 3

Carboplatin

Approved

Phase 2

41575-94-4

10339178 38904

Paclitaxel

Approved, Vet_approved

Phase 2

33069-62-4

36314

Capecitabine

Approved, Investigational

Phase 2

154361-50-9

60953

Raspberry

Approved

Phase 1, Phase 2

Hyaluronic acid

Approved, Vet_approved

Phase 2

9004-61-9

53477741

Bortezomib

Approved, Investigational

Phase 2

179324-69-7

387447 93860

Sargramostim

Approved, Investigational

Phase 2

123774-72-1

Sorafenib

Approved, Investigational

Phase 2

284461-73-0

216239

Dasatinib

Approved, Investigational

Phase 2

302962-49-8

3062316

Acetylcysteine

Approved, Investigational

Phase 2

616-91-1

581 12035

Lapatinib

Approved, Investigational

Phase 2

231277-92-2, 388082-78-8

208908

Irinotecan

Approved, Investigational

Phase 2

97682-44-5, 100286-90-6

60838

Avelumab

Approved, Investigational

Phase 2

1537032-82-8

Cemiplimab

Approved, Investigational

Phase 2

1801342-60-8

Nivolumab

Approved

Phase 2

946414-94-4

Miconazole

Approved, Investigational, Vet_approved

Phase 2

22916-47-8

4189

Clotrimazole

Approved, Vet_approved

Phase 2

23593-75-1

2812

Pembrolizumab

Approved

Phase 2

1374853-91-4

254741536

Doxepin

Approved, Investigational

Phase 2

1668-19-5

667468 667477

Histamine

Approved, Investigational

Phase 2

51-45-6

774

Diphenhydramine

Approved, Investigational

Phase 2

147-24-0, 58-73-1

3100

Promethazine

Approved, Investigational

Phase 2

60-87-7

4927

Celecoxib

Approved, Investigational

Phase 2

169590-42-5

2662

Interventional clinical trials:

(show top 50) (show all 198)

#	Name	Status	NCT ID	Phase	Drugs
1	the Comparison of Voice Quality in Early Laryngeal Cancer Between Surgery and Radiotherapy	Unknown status	NCT00497588	Phase 3
2	A Multicentre, Randomised, Phase III Clinical Trial Comparing Accelerated Radiotherapy With Accelerated Radiotherapy Plus Carbogen and Nicotinamide (ARCON) in Clinical Stage T2-4 Laryngeal Carcinoma.	Completed	NCT00147732	Phase 3
3	Double Blind Randomised Study of 2 Days and 5 Days Cefazolin Prophylactic Method in Laryngeal Oncologic Surgery	Completed	NCT00467948	Phase 3	cefazolin
4	Randomized Study Comparing Induction Chemotherapy With Docetaxel, Cisplatin, 5FU Versus Cisplatin, 5 FU in Patients With T3 and T4 Larynx and Hypopharynx Carcinoma	Completed	NCT00169182	Phase 3	DOCETAXEL;Cisplatin;5-Fluoro-3-Pyridinecarboxylic Acid
5	Phase III Trial Comparing Conventional RT With Concomitant CT Versus Accelerated RT With Concomitant CT Versus Very Accelerated RT Alone in Patients With Head and Neck Squamous Cell Carcinoma	Completed	NCT00158652	Phase 3	5FU, Paraplatin
6	A Randomized Trial Evaluating a Very Intense Radiotherapy-Chemotherapy Regimen Versus a Very Accelerated Radiotherapy in Advanced Head and Neck Squamous Cell Carcinoma	Completed	NCT00162708	Phase 2, Phase 3	CDDP, 5 Fu
7	DEPISTORL - THANCS (Trial of Head And Neck Cancer Screening) Randomized Multicenter Trial to Assess the Impact of a Screening Program for Heavy Alcohol Drinkers and Smokers Treated in Alcohol Addiction Clinics on Upper Aerodigestive Tract Cancer Mortality.	Completed	NCT00359645	Phase 3
8	A Phase III Randomized Trial of Docetaxel Based Induction Chemotherapy in Patients With N2/N3 Locally Advanced Head and Neck Cancer	Completed	NCT00117572	Phase 3	docetaxel;cisplatin;hydroxyurea;fluorouracil
9	A Phase II/III Trial of Chemotherapy + Cetuximab vs Chemotherapy + Bevacizumab vs Atezolizumab + Bevacizumab Following Progression on Immune Checkpoint Inhibition in Recurrent/Metastatic Head and Neck Cancers	Recruiting	NCT05063552	Phase 2, Phase 3	Carboplatin;Cisplatin;Docetaxel
10	Effects of Oral Aloe Vera Juice on Chemotherapy and Radiation-induced Oral Mucositis and Esophagitis: a Single-blind Randomized Controlled Trial	Recruiting	NCT05369234	Phase 3	Carafate
11	Randomized Phase II/III Trial of Radiotherapy With Concurrent MEDI4736 (Durvalumab) vs. Radiotherapy With Concurrent Cetuximab in Patients With Locoregionally Advanced Head and Neck Cancer With a Contraindication to Cisplatin	Active, not recruiting	NCT03258554	Phase 2, Phase 3
12	Phase III Randomized Clinical Trial to Compare Results of Concurrent Chemo-radiation With Surgery and Postoperative Radiotherapy/Chemoradiotherapy in Advanced Laryngeal and Hypopharyngeal Cancers	Terminated	NCT00128817	Phase 3
13	Phase II Organ Preservation Trial Using Cisplatin Concomitant With Radiation Therapy in Advanced Laryngeal Cancer Patients Who Have Responded to Induction Chemotherapy With Taxotere, Cisplatin, and 5-Fluorouracil (TPF)	Unknown status	NCT01073683	Phase 2	Taxotere (Docetaxel), Cisplatin, 5FU
14	A Phase II Study of Induction Chemotherapy Followed by Concomitant Paclitaxel (1 Hour Infusion), Fluorouracil, Hydroxyurea and Hyperfractionated Radiotherapy for Advanced Oral, Pharynx and Larynx Cancer	Unknown status	NCT00004094	Phase 2	carboplatin;fluorouracil;hydroxyurea;paclitaxel
15	Resistance Training During Radiation Therapy for Pharyngeal or Laryngeal Cancer	Completed	NCT00827164	Phase 2
16	Clinical Outcomes Modeling for Laryngectomy Surgery Patients and Efficacy of Hyperbaric Oxygen Therapy	Completed	NCT00026975	Phase 2
17	Concomitant Chemotherapy AND Bcl-xL Inhibitor (AT-101) For Bio-selection For Organ Preservation In Patients With Advanced Laryngeal Cancer	Completed	NCT01633541	Phase 2	AT-101;Docetaxel;Cisplatin;Carboplatin
18	Combination of Cryosurgey and NK Immunotherapy for Recurrent Laryngeal Cancer	Completed	NCT02849314	Phase 1, Phase 2
19	Phase 1-2 18F-FPPRGD2 PET/CT or PET/MRI Imaging of αvβ3 Integrins Expression as a Biomarker of Angiogenesis	Completed	NCT01806675	Phase 1, Phase 2	18F-fludeoxyglucose (18F-FDG);18F-FPPRGD2
20	Food-Based Modulation of Biomarkers in Human Tissues at High-Risk for Oral Cancer	Completed	NCT01469429	Phase 1, Phase 2	chemoprevention
21	Injection Thyroplasty During Transoral Laser Microsurgery for Early Glottic Cancer: Single-blinded Randomized Controlled Trial	Completed	NCT04525066	Phase 2	Hyaluronic acid
22	A Phase II, Randomized, Open-Label, Single Center Study In Patients With Advanced Head And Neck Cancer To Investigate Efficacy And Safety Of Standard Chemoradiation And Add-On Concurrent Cetuximab ± Consolidation Cetuximab	Completed	NCT01435252	Phase 2	Cetuximab
23	Randomised Phase II Study of GM-CSF to Reduce Severity of Mucositis Caused by Accelerated Radiotherapy of Laryngeal Cancer	Completed	NCT00004256	Phase 2
24	Adaptive, Image-guided, Intensity-modulated Radiotherapy for Head and Neck Cancer in the Reduced Volumes of Elective Neck: a Multicenter, Two-arm, Randomized Phase II Trial.	Completed	NCT01287390	Phase 2
25	A Phase II Trial With Radiotherapy Plus Cetuximab to Evaluate Specific Survival Free of Laryngectomy in Patients With Resectable and Locally Advanced Larynx Cancer, After Treatment With TPF	Completed	NCT00765011	Phase 2	TPF, radiotherapy and cetuximab
26	A Prospective Non-Inferiority Trial of the Use of Adaptive Radiotherapy for Head and Neck Cancer Undergoing Radiation Therapy	Completed	NCT03096808	Phase 2
27	Larynx Preservation With Induction Chemotherapy (Cisplatin, 5FU, Docetaxel) Followed by Radiotherapy Combined With Either Cisplatin or Cetuximab in Laryngopharyngeal Squamous Cell Carcinoma - A Randomised Phase II Study	Completed	NCT00169247	Phase 2	cetuximab;Cisplatin
28	F-18 Fluorothymidine (FLT) PET Imaging for Early Evaluation of Response to Chemoradiation Therapy in Patients With Head and Neck Squamous Cell Carcinoma (HNSCC)	Completed	NCT00721799	Phase 2	18F-Fluorothymidine PET scan
29	Investigating the Impact of Tailored Reports on Anxiety	Completed	NCT00127465	Phase 1, Phase 2
30	Randomised Phase II Pilot Study: Induction Chemotherapy With Docetaxel, Cisplatin and Cetuximab Versus Docetaxel, Cisplatin and 5 FU Followed by Radiotherapy With Cetuximab for Locally Advanced or Not Resectable Carcinoma of the Head and Neck	Completed	NCT01884259	Phase 2	Docetaxel;Cisplatin;5-fluorouracil
31	Phase II Trial Of Induction Chemotherapy Followed By Attenuated Chemoradiotherapy For Locally Advanced Head And Neck Squamous Cell Carcinoma Associated With Human Papillomavirus (HPV)	Completed	NCT02048020	Phase 2	paclitaxel;carboplatin
32	A Phase 2 Study of Dasatinib in Head and Neck Squamous Cell Carcinoma	Completed	NCT00507767	Phase 2	dasatinib
33	Phase II Study of Concomitant Fluorouracil, Hydroxyurea, Cetuximab and Hyperfractionated Intensity Modulated Radiation Therapy for Locally Advanced Head and Neck Cancer	Completed	NCT00462735	Phase 2	Cetuximab;Hydroxyurea;Fluorouracil
34	A Phase II Study of AZD0530 for Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)	Completed	NCT00513435	Phase 2	saracatinib
35	A Randomized Phase II Trial of Bevacizumab to Control Brain Radiation Damage	Completed	NCT00492089	Phase 2	bevacizumab;placebo
36	Phase II Study of Sunitinib Malate in Head and Neck Squamous Cell Carcinoma	Completed	NCT00387335	Phase 2	sunitinib malate
37	Multicenter Randomized Phase II Study of Erlotinib, Cisplatin and Radiotherapy Versus Cisplatin and Radiotherapy in Patients With Stage III and IV Squamous Cell Carcinoma of the Head and Neck	Completed	NCT00410826	Phase 2	erlotinib hydrochloride;cisplatin
38	A Randomized, Double-Blind Pilot Study of N-Acetylcysteine Mucoadherent Rinse Versus Placebo for Thickened Secretions and Mucositis Secondary to Chemoradiotherapy in the Management of Head and Neck Malignancies	Completed	NCT02123511	Phase 2	acetylcysteine
39	A Phase 2 Trial of GW572016 in Patients With Metastatic and Recurrent Squamous Cell Carcinomas of the Head and Neck	Completed	NCT00114283	Phase 2	lapatinib ditosylate
40	Phase II Two Arm Trial of the Proteasome Inhibitor, PS-341 (Velcade TM) in Combination With Irinotecan or PS-341 Alone Followed by the Addition of Irinotecan at Time of Progression in Patients With Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN)	Completed	NCT00103259	Phase 2	bortezomib;irinotecan hydrochloride
41	A Phase II Study Of GW572016 In Squamous Cell Carcinoma Of The Head And Neck (SCCHN)	Completed	NCT00098631	Phase 2	lapatinib ditosylate
42	A Phase I and Phase II Study of OSI-774 in Combination With Docetaxel in Squamous Cell Carcinoma of the Head and Neck	Completed	NCT00055770	Phase 1, Phase 2	erlotinib hydrochloride;docetaxel
43	Phase I/II Dose Escalation Trial of Induction and Concomitant Erlotinib and Celecoxib With Radiation Therapy for Treatment of Poor Prognosis Head and Neck Cancer, Including Reirradiation	Completed	NCT00970502	Phase 1, Phase 2	erlotinib + celecoxib
44	Phase II Evaluation of BAY 43-9006 (NSC-724772) in Patients With Recurrent or Metastatic Head and Neck Cancer	Completed	NCT00096512	Phase 2	sorafenib tosylate
45	A Phase 2 Study of SB-715992 in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck	Completed	NCT00095628	Phase 2	ispinesib
46	A Randomized Phase II Study of BMS-247550 (NSC #710428) Given Daily x 5 Days Every 3 Weeks or Weekly in Patients With Metastatic or Recurrent Squamous Cell Cancer of the Head and Neck	Completed	NCT00033618	Phase 2	ixabepilone
47	Phase II Randomized Trial of the Combination of Cetuximab and Sorafenib or Single Agent Cetuximab in Patients With Refractory, Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN)	Completed	NCT00939627	Phase 2	sorafenib tosylate
48	A Phase II Study of Capecitabine and Lapatinib in Squamous Cell Carcinoma of the Head and Neck	Completed	NCT01044433	Phase 2	lapatinib ditosylate;capecitabine
49	A Phase I, and Biologic Correlative Study of Erlotinib, in Combination With Cetuximab and Bevacizumab in Patients With Metastatic Renal Cell Carcinoma	Completed	NCT00101348	Phase 1, Phase 2	erlotinib hydrochloride
50	A Pharmacogenetic and Pharmacodynamic Study of Erlotinib (OSI-774) Toxicity in Patients With Advanced Solid Tumors	Completed	NCT00063895	Phase 1, Phase 2	erlotinib hydrochloride

Search NIH Clinical Center for Larynx Cancer

Cochrane evidence based reviews: laryngeal neoplasms

Sources

Genetic Tests for Larynx Cancer

Sources

Anatomical Context for Larynx Cancer

Organs/tissues related to Larynx Cancer:

FMA: Larynx

MalaCards : Lymph Node, Lung, Trachea, Endothelial, Thyroid, Breast, Liver

Sources

Publications for Larynx Cancer

Articles related to Larynx Cancer:

(show top 50) (show all 9877)

#	Title	Authors	PMID	Year
1	Regulation of the cell cycle gene, BTG2, by miR-21 in human laryngeal carcinoma. ⁶² ⁴⁶	Liu M...Tang H	19546886	2009
2	Laryngeal carcinoma lymph node metastasis and disease-free survival correlate with MASPIN nuclear expression but not with EGFR expression: a series of 108 cases. ⁵³ ⁶²	Marioni G...Blandamura S	20052590	2010
3	SH3GL2 gene participates in MEK-ERK signal pathway partly by regulating EGFR in the laryngeal carcinoma cell line Hep2. ⁵³ ⁶²	Shang C...Sun K	20512084	2010
4	Expression of Epidermal Growth Factor Receptor variant III in laryngeal carcinoma tissues. ⁵³ ⁶²	Yang B...Cao J	19427146	2009
5	[Expression of E-cadherin and uPA and their prognostic value in carcinoma of human larynx.]. ⁵³ ⁶²	Wu HY...Gao X	20193619	2009
6	EGFR immunoexpression and peripheral blood cytokine secretion as potential biomarkers of tumor behavior in laryngeal squamous cell carcinoma. ⁵³ ⁶²	Starska K...Lukomski M	19789511	2009
7	Potential role of Notch1 signaling pathway in laryngeal squamous cell carcinoma cell line Hep-2 involving proliferation inhibition, cell cycle arrest, cell apoptosis, and cell migration. ⁵³ ⁶²	Jiao J...Lu Z	19724860	2009
8	Laryngeal cancer risk associated with smoking and alcohol consumption is modified by genetic polymorphisms in ERCC5, ERCC6 and RAD23B but not by polymorphisms in five other nucleotide excision repair genes. ⁵³ ⁶²	Abbasi R...Popanda O	19444904	2009
9	[Expression of EMS1 protein and its clinical significance in laryngeal carcinoma]. ⁵³ ⁶²	Li L...Liu S	19947248	2009
10	[Relationships of human laryngeal squamous cell carcinomas with the expression of VEGF-C and VEGFR-3]. ⁵³ ⁶²	Wang Z...Chen Y	19813623	2009
11	The role of p53, PCNA and Ki-67 as outcome predictors in the treatment of laryngeal cancer. ⁵³ ⁶²	Sarafoleanu D...Sarafoleanu C	20108544	2009
12	Impact of EGFR immunoexpression on STAT3 activation and association with proinflammatory/regulatory cytokine pattern in laryngeal squamous cell carcinoma. ⁵³ ⁶²	Starska K...Lukomski M	19148533	2009
13	Radiotherapy in laryngeal carcinoma: can a panel of 13 markers predict response? ⁵³ ⁶²	Wildeman MA...van den Brekel MW	19160427	2009
14	[Impact of tobacco smoking on biologic background of laryngeal squamous cell carcinoma]. ⁵³ ⁶²	Bodnar M...Marszalek A	20301890	2009
15	Adhesion/growth-regulatory tissue lectin galectin-1 in relation to angiogenesis/lymphocyte infiltration and prognostic relevance of stromal up-regulation in laryngeal carcinomas. ⁵³ ⁶²	Saussez S...Gabius HJ	19331133	2009
16	Galectin-3 upregulation during tumor progression in head and neck cancer. ⁵³ ⁶²	Saussez S...Gabius HJ	18677282	2008
17	Retinoblastoma gene abnormalities in early laryngeal cancer. ⁵³ ⁶²	Rafferty M...Jones A	18172658	2008
18	MASPIN subcellular localization and expression in oral cavity squamous cell carcinoma. ⁵³ ⁶²	Marioni G...Blandamura S	18236066	2008
19	[Relative factors analysis including carcinoma marker, molecular margin and clinical factors on laryngeal carcinoma recurrence]. ⁵³ ⁶²	Yi H...Li Y	18800676	2008
20	Prognostic value of expression of p53, proliferating cell nuclear antigen, and c-erbB-2 in laryngeal carcinoma. ⁵³ ⁶²	Micozkadioglu D...Cinel L	18509272	2008
21	Nuclear localization of mammary serine protease inhibitor (MASPIN): is its impact on the prognosis in laryngeal carcinoma due to a proapoptotic effect? ⁵³ ⁶²	Marioni G...Blandamura S	18439947	2008
22	Short hairpin ribonucleic acid targeting the telomerase catalytic unit of messenger ribonucleic acid significantly limits the growth of laryngeal squamous cell carcinoma in nude mice. ⁵³ ⁶²	Zhou XH...Tao ZZ	17592663	2008
23	EGFR, HER2, and HER3 expression in laryngeal primary tumors and corresponding metastases. ⁵³ ⁶²	Wei Q...Carlsson J	18172732	2008
24	Clinicopathological significance of the fragile histidine triad transcription protein expression in laryngeal carcinogenesis. ⁵³ ⁶²	Kitamura K...Suzuki M	18357366	2008
25	Cortactin expression predicts poor survival in laryngeal carcinoma. ⁵³ ⁶²	Gibcus JH...van der Wal JE	18268491	2008
26	Inhibition of apoptosis in human laryngeal cancer cells by E6 and E7 oncoproteins of human papillomavirus 16. ⁵³ ⁶²	Liu HC...van Hasselt CA	17668439	2008
27	[Expression of Survivin, Caspase-3 and p53 in surgical margin of laryngeal squamous cell carcinoma and their relationship]. ⁵³ ⁶²	Du J...Su Y	18476631	2008
28	[Expression and implication of CD44 and nm23-H1 proteins in laryngeal carcinoma]. ⁵³ ⁶²	Yang X...Yang Z	18476632	2008
29	[Expression of FHIT gene protein in laryngeal carcinoma]. ⁵³ ⁶²	Cao L...Wang B	18476633	2008
30	[Effect of interferon-gamma on the expression of vascular endothelial growth factor C on Hep-2 laryngeal carcinoma cell lines]. ⁵³ ⁶²	Chen J...Wang J	18476628	2008
31	Laryngeal carcinoma recurrence rate and disease-free interval are related to CD105 expression but not to vascular endothelial growth factor 2 (Flk-1/Kdr) expression. ⁵³ ⁶²	Marioni G...Blandamura S	18383901	2008
32	Suppression of survivin expression by short hairpin RNA induces apoptosis in human laryngeal carcinoma cells. ⁵³ ⁶²	Chen XM...Pan XL	18391576	2008
33	Application of primary cell cultures of laryngeal carcinoma and laser scanning cytometry in the evaluation of tumor reactivity to cisplatinum. ⁵³ ⁶²	Klatka J...Rolinski J	18519232	2008
34	Expression of cyclooxygenase-2, vascular endothelial growth factor and matrix metalloproteinase-2 in patients with primary laryngeal carcinoma: a tissue microarray study. ⁵³ ⁶²	Dong P...Lu G	17888194	2007
35	[Relevance of Endoglin (CD105) VEGF and p53 with invasion metastasis and prognosis of laryngeal carcinoma]. ⁵³ ⁶²	Li Q...Peng P	18330257	2007
36	Soluble EMMPRIN (extra-cellular matrix metalloproteinase inducer) stimulates the migration of HEp-2 human laryngeal carcinoma cells, accompanied by increased MMP-2 production in fibroblasts. ⁵³ ⁶²	Hanata K...Ishikawa K	18431027	2007
37	[Correlation of membrane type I matrix metalloproteinase (MT1-MMP) expression with clinicomorphological features of tumor front in squamous cell carcinoma of the larynx]. ⁵³ ⁶²	Starska K...Lewy-Trenda I	18080692	2007
38	[The expression of MMP-2, E-cadherin in supraglottic carcinoma and their relationship with cervical lymph node metastasis]. ⁵³ ⁶²	Sun C...Wang Y	18062285	2007
39	[Expression and role of survivin in laryngeal squamous cell carcinoma and laryngeal papilloma in adults]. ⁵³ ⁶²	Xie H...Song F	17634026	2007
40	[Elemene in the treatment of the transplantable model of human laryngeal squamous carcinoma in nude mice]. ⁵³ ⁶²	Cao Z...Ji W	17634027	2007
41	[Morphological tumor front grading and matrix metalloproteinases type I expression as a prognostic parameter of the presence of lymph node micrometastases in laryngeal carcinoma]. ⁵³ ⁶²	Lukomski M...Starska K	18552024	2007
42	[Assay of matrix metalloproteinase levels and their endogenous inhibitors in patients with laryngeal carcinoma]. ⁵³ ⁶²	Klisho EV...Shishkin DA	17649730	2007
43	The role of host immune response and apoptosis in patients with laryngeal squamous cell carcinoma. ⁵³ ⁶²	Gomatos IP...Ferekidou E	17264532	2007
44	Prognostic significance of metallothionein, p53 protein and Ki-67 antigen expression in laryngeal cancer. ⁵³ ⁶²	Pastuszewski W...Zabel M	17352251	2007
45	Overexpression of human 27 kDa heat shock protein in laryngeal cancer cells confers chemoresistance associated with cell growth delay. ⁵³ ⁶²	Lee JH...Lee JH	16906418	2007
46	Maspin nuclear localization is related to reduced density of tumour-associated micro-vessels in laryngeal carcinoma. ⁵³ ⁶²	Marioni G...Blandamura S	17214364	2006
47	5-fluorouracil mediates apoptosis and G1/S arrest in laryngeal squamous cell carcinoma via a p53-independent pathway. ⁵³ ⁶²	Liu HC...van Hasselt CA	17207318	2006
48	[Quantitative analysis of epidermal growth factor receptor mRNA in laryngeal carcinoma by reverse transcription-real time polymerase chain reaction with TagMan probe]. ⁵³ ⁶²	Chen J...Cao J	17190429	2006
49	[Relationship among lymphangiogenesis, vascular endothelial growth factor-C mRNA expression and cervical lymphatic metastasis in laryngeal carcinoma]. ⁵³ ⁶²	Tai XH...Sun XH	17039808	2006
50	Human papillomavirus and Epstein-Barr virus infection, p53 expression, and cellular proliferation in laryngeal carcinoma. ⁵³ ⁶²	de Oliveira DE...Bacchi CE	16891205	2006

Sources

Genes for Larynx Cancer

Genes related to Larynx Cancer (1 elite genes):

(show top 50) (show all 53)

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence	PubMed IDs
1	MIR21	MicroRNA 21	RNA Gene	370.88	Causal ⁴⁶ DISEASES inferred ¹⁴ ¹⁴ ¹⁴ ¹⁴	19546886
2	DLEU2	Deleted In Lymphocytic Leukemia 2	RNA Gene	156.72	Experimental evidence: Expression ³⁷ DISEASES inferred ¹⁴ ¹⁴
3	FAM3D-AS1	FAM3D Antisense RNA 1	RNA Gene	150	Experimental evidence: Regulation ³⁷	25904139
4	GSTM1	Glutathione S-Transferase Mu 1	Protein Coding	23.71	DISEASES inferred ¹⁴ ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	15127559 11097350 9456238 (more) 12359356 12748560 10067818 14594555 11477586
5	NME1	NME/NM23 Nucleoside Diphosphate Kinase 1	Protein Coding	23.12	DISEASES inferred ¹⁴ ¹⁴ Novoseek inferred ⁵³	12768677 12014221 11265374 (more) 12815897 9616278 9642340 18476632 11080791 11387948 12764847 8635091 11189167
6	GSTM3	Glutathione S-Transferase Mu 3	Protein Coding	21.94	DISEASES inferred ¹⁴ ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	10067818 12359356 10407823
7	TP53	Tumor Protein P53	Protein Coding	21.87	DISEASES inferred ¹⁴ ¹⁴ Novoseek inferred ⁵³	11699821 12600081 8386140 (more) 12815897 11205233 12881872 7654413 18800676 9687893 12768762 9193221 15835821 11189420 18330257 8762527 7781800 10073037 8780536 11265384 17207318 10875157 9874454 7788934 10499619 9097709 17352251 20108544 9563667 9197477 19160427 18476631 11829192 11400228 12768677 9197495 18559058 18519232 16075975 15067348 11200824 9583028 10323025 15039212 12536563 10852523 16891205 16809096 15831046 12175687 10810258 10337529 8616872 9445184 15467627 12656410 12541678 9267820 19072995 18509272 14551784 10953333 10419041 19724860 11520092 12761983
8	CCND1	Cyclin D1	Protein Coding	20.28	DISEASES inferred ¹⁴ ¹⁴ Novoseek inferred ⁵³	15354413 17139501 14551784 (more) 16881553 18329328 11189154 9738577 9816104 15467627 19160427 12669430 18268491 16270530 9545767 15509364 8616872 19724860 12649172
9	MIR139	MicroRNA 139	RNA Gene	20.08	DISEASES inferred ¹⁴ ¹⁴ ¹⁴ ¹⁴
10	MIR31	MicroRNA 31	RNA Gene	19.82	DISEASES inferred ¹⁴ ¹⁴ ¹⁴ ¹⁴
11	MIR106B	MicroRNA 106b	RNA Gene	19.65	DISEASES inferred ¹⁴ ¹⁴ ¹⁴ ¹⁴
12	MIR143	MicroRNA 143	RNA Gene	19.5	DISEASES inferred ¹⁴ ¹⁴ ¹⁴ ¹⁴
13	MIR145	MicroRNA 145	RNA Gene	19.46	DISEASES inferred ¹⁴ ¹⁴ ¹⁴ ¹⁴
14	MKI67	Marker Of Proliferation Ki-67	Protein Coding	19.35	DISEASES inferred ¹⁴ ¹⁴ Novoseek inferred ⁵³	17352251 10974882 11265375 (more) 14524174 9173391 10456281 9583028 14575829 14551784 16270530 20301890 12520353 11200824
15	MIR486-1	MicroRNA 486-1	RNA Gene	19.18	DISEASES inferred ¹⁴ ¹⁴ ¹⁴ ¹⁴
16	BCL2	BCL2 Apoptosis Regulator	Protein Coding	19.06	DISEASES inferred ¹⁴ ¹⁴ Novoseek inferred ⁵³	12600081 15283295 10456279 (more) 17264532 11520092 11070692 12656410 16675913 19724860 12175687 15831046 15243561 18519232 9591537 10091732 11829192 11400228 15852789 11309054 15803918 10419041 17476972
17	EGFR	Epidermal Growth Factor Receptor	Protein Coding	18.98	DISEASES inferred ¹⁴ ¹⁴ Novoseek inferred ⁵³	19427146 11721445 12541404 (more) 9639720 19148533 17190429 15338866 1516034 18172732 18329328 10932015 9271009 8291440 20052590 20512084 9197492 19789511 9197495 14666705 8616872
18	MIR148A	MicroRNA 148a	RNA Gene	18.75	DISEASES inferred ¹⁴ ¹⁴ ¹⁴ ¹⁴
19	GSTP1	Glutathione S-Transferase Pi 1	Protein Coding	18.73	DISEASES inferred ¹⁴ ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	10067818 12359356
20	TERT	Telomerase Reverse Transcriptase	Protein Coding	18.52	DISEASES inferred ¹⁴ ¹⁴ Novoseek inferred ⁵³	17592663 19159530
21	MIR204	MicroRNA 204	RNA Gene	18.19	DISEASES inferred ¹⁴ ¹⁴ ¹⁴ ¹⁴
22	MIR744	MicroRNA 744	RNA Gene	18.16	DISEASES inferred ¹⁴ ¹⁴ ¹⁴ ¹⁴
23	CTSD	Cathepsin D	Protein Coding	18.09	DISEASES inferred ¹⁴ ¹⁴ Novoseek inferred ⁵³	10850757 9135974 8962695 (more) 8608976 11080791 10652611 11299783 8443785 12528259 11012985
24	MIR155	MicroRNA 155	RNA Gene	18.08	DISEASES inferred ¹⁴ ¹⁴ ¹⁴ ¹⁴
25	MIR423	MicroRNA 423	RNA Gene	18	DISEASES inferred ¹⁴ ¹⁴ ¹⁴ ¹⁴
26	MIR144	MicroRNA 144	RNA Gene	17.99	DISEASES inferred ¹⁴ ¹⁴ ¹⁴ ¹⁴
27	MIR196A1	MicroRNA 196a-1	RNA Gene	17.61	DISEASES inferred ¹⁴ ¹⁴ ¹⁴ ¹⁴
28	MIR27A	MicroRNA 27a	RNA Gene	17.52	DISEASES inferred ¹⁴ ¹⁴ ¹⁴ ¹⁴
29	MIR17	MicroRNA 17	RNA Gene	17.46	DISEASES inferred ¹⁴ ¹⁴ ¹⁴ ¹⁴
30	MIR125A	MicroRNA 125a	RNA Gene	17.33	DISEASES inferred ¹⁴ ¹⁴ ¹⁴ ¹⁴
31	MIR140	MicroRNA 140	RNA Gene	17.24	DISEASES inferred ¹⁴ ¹⁴ ¹⁴ ¹⁴
32	MIR149	MicroRNA 149	RNA Gene	16.99	DISEASES inferred ¹⁴ ¹⁴ ¹⁴ ¹⁴
33	MMP2	Matrix Metallopeptidase 2	Protein Coding	16.91	DISEASES inferred ¹⁴ ¹⁴ Novoseek inferred ⁵³	17888194 18062285 18431027 (more) 10320094 17649730 11843925
34	MIR142	MicroRNA 142	RNA Gene	16.84	DISEASES inferred ¹⁴ ¹⁴ ¹⁴ ¹⁴
35	MMP14	Matrix Metallopeptidase 14	Protein Coding	16.83	DISEASES inferred ¹⁴ ¹⁴ Novoseek inferred ⁵³	10491020 18552024 15563089 (more) 18080692 15506641 14729463
36	MIR210	MicroRNA 210	RNA Gene	16.83	DISEASES inferred ¹⁴ ¹⁴ ¹⁴ ¹⁴
37	MIR330	MicroRNA 330	RNA Gene	16.82	DISEASES inferred ¹⁴ ¹⁴ ¹⁴ ¹⁴
38	CTTN	Cortactin	Protein Coding	16.8	DISEASES inferred ¹⁴ ¹⁴ Novoseek inferred ⁵³	19947248 18268491
39	SERPINB5	Serpin Family B Member 5	Protein Coding	16.79	DISEASES inferred ¹⁴ ¹⁴ Novoseek inferred ⁵³	18439947 15842640 17214364 (more) 18236066
40	GSTT1	Glutathione S-Transferase Theta 1	Protein Coding	16.7	Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	8561822 11097350 9456238 (more) 12359356 10067818
41	MIR338	MicroRNA 338	RNA Gene	16.67	DISEASES inferred ¹⁴ ¹⁴ ¹⁴ ¹⁴
42	MIR493	MicroRNA 493	RNA Gene	16.64	DISEASES inferred ¹⁴ ¹⁴ ¹⁴ ¹⁴
43	MIR26B	MicroRNA 26b	RNA Gene	16.62	DISEASES inferred ¹⁴ ¹⁴ ¹⁴ ¹⁴
44	MIR141	MicroRNA 141	RNA Gene	16.53	DISEASES inferred ¹⁴ ¹⁴ ¹⁴ ¹⁴
45	MIR93	MicroRNA 93	RNA Gene	16.52	DISEASES inferred ¹⁴ ¹⁴ ¹⁴ ¹⁴
46	MIR296	MicroRNA 296	RNA Gene	16.52	DISEASES inferred ¹⁴ ¹⁴ ¹⁴ ¹⁴
47	MIR135A1	MicroRNA 135a-1	RNA Gene	16.44	DISEASES inferred ¹⁴ ¹⁴ ¹⁴ ¹⁴
48	MIR216A	MicroRNA 216a	RNA Gene	16.42	DISEASES inferred ¹⁴ ¹⁴ ¹⁴ ¹⁴
49	MIR654	MicroRNA 654	RNA Gene	16.36	DISEASES inferred ¹⁴ ¹⁴ ¹⁴ ¹⁴
50	MIRLET7E	MicroRNA Let-7e	RNA Gene	16.34	DISEASES inferred ¹⁴ ¹⁴ ¹⁴ ¹⁴

Sources

Variations for Larynx Cancer

Sources

Expression for Larynx Cancer

Search GEO for disease gene expression data for Larynx Cancer.

Sources

Pathways for Larynx Cancer

Pathways related to Larynx Cancer according to GeneCards Suite gene sharing:

(show all 19)

#	Super pathways	Score	Top Affiliating Genes
1	Nuclear receptors meta-pathway ⁷⁴ Show member pathways NRF2 pathway ⁷⁴	12.53	CCND1 EGFR GSTM1 GSTM3 GSTP1
2	Malignant pleural mesothelioma ⁷⁴	12.41	TP53 TERT EGFR CCND1 BCL2
3	DNA Damage ³	12.34	TP53 MKI67 GSTP1 CCND1
4	MAPK Signaling: Mitogens ⁶⁵ Show member pathways Akt Signaling Pathway ⁶⁵	12.03	TP53 EGFR CCND1 BCL2
5	Integrated breast cancer pathway ⁷⁴	11.8	TP53 EGFR CCND1 BCL2
6	Interleukin-4 and Interleukin-13 signaling ⁶⁶	11.79	TP53 CCND1 BCL2
7	DNA damage response (only ATM dependent) ⁷⁴	11.76	TP53 CCND1 BCL2
8	Small cell lung cancer ⁷⁴	11.72	TP53 CCND1 BCL2
9	Validated targets of C-MYC transcriptional activation ⁶¹	11.62	TP53 TERT NME1
10	C-MYB transcription factor network ⁶¹	11.6	GSTM1 CCND1 BCL2
11	Cell differentiation - expanded index ⁷⁴ Show member pathways Cell differentiation - index ⁷⁴	11.58	MIR486-1 MIR145 MIR143
12	Regulation of Telomerase ⁶¹	11.5	TERT EGFR CCND1
13	miRNAs involvement in the immune response in sepsis ⁷⁴	11.43	MIR21 MIR145 MIR106B
14	Busulfan Pathway, Pharmacodynamics ⁶⁰ Show member pathways Catalytic cycle of mammalian flavin-containing monooxygenases (FMOs) ⁷⁴ Defective FMO3 causes TMAU ⁶⁶ FMO oxidises nucleophiles ⁶⁶	11.2	GSTP1 GSTM1 BCL2
15	Head and neck squamous cell carcinoma ⁷⁴	11.12	TP53 TERT EGFR CCND1
16	Inhibition of Signaling by Overexpressed EGFR ⁶⁶ Show member pathways Estrogen-dependent nuclear events downstream of ESR-membrane signaling ⁶⁶ Signaling by Overexpressed Wild-Type EGFR in Cancer ⁶⁶	11.03	EGFR CCND1 BCL2
17	Bladder cancer ⁷⁴	10.93	TP53 EGFR CCND1
18	miRNAs involved in DNA damage response ⁷⁴	10.93	TP53 MIR21 MIR145 MIR143 MIR106B CCND1
19	MicroRNA network associated with chronic lymphocytic leukemia ⁷⁴	10.21	TP53 BCL2

Sources

GO Terms for Larynx Cancer

Cellular components related to Larynx Cancer according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	RISC complex	GO:0016442	9.5	MIR486-1 MIR31 MIR21 MIR148A MIR145 MIR143

Biological processes related to Larynx Cancer according to GeneCards Suite gene sharing:

(show all 27)

#	Name	GO ID	Score	Top Affiliating Genes
1	negative regulation of apoptotic process	GO:0043066	10.32	TP53 TERT MIR21 GSTP1 EGFR BCL2
2	cellular response to hypoxia	GO:0071456	10.09	TP53 TERT MIR106B BCL2
3	positive regulation of G1/S transition of mitotic cell cycle	GO:1900087	10.08	CCND1 EGFR TERT
4	glutathione metabolic process	GO:0006749	10.06	GSTP1 GSTM3 GSTM1
5	positive regulation of angiogenesis	GO:0045766	10.02	TERT MIR31 MIR21 MIR143
6	positive regulation of miRNA transcription	GO:1902895	10.01	TP53 TERT EGFR
7	negative regulation of miRNA maturation	GO:1903799	9.93	TP53 TERT
8	regulation of ERK1 and ERK2 cascade	GO:0070372	9.89	MIR145 GSTP1 EGFR
9	cellular detoxification of nitrogen compound	GO:0070458	9.88	GSTM3 GSTM1
10	cell population proliferation	GO:0008283	9.88	BCL2 CCND1 EGFR MKI67 TP53
11	B cell lineage commitment	GO:0002326	9.86	TP53 BCL2
12	nitrobenzene metabolic process	GO:0018916	9.84	GSTM1 GSTM3
13	glutathione derivative biosynthetic process	GO:1901687	9.83	GSTM1 GSTP1
14	negative regulation of angiogenesis	GO:0016525	9.81	MIR21 MIR145 MIR143 MIR106B
15	response to UV-A	GO:0070141	9.78	EGFR CCND1
16	T cell lineage commitment	GO:0002360	9.77	TP53 BCL2
17	miRNA-mediated gene silencing	GO:0035195	9.77	MIR486-1 MIR31 MIR21 MIR148A MIR145 MIR143
18	angiotensin-activated signaling pathway	GO:0038166	9.63	MIR145 MIR143
19	negative regulation of cardiac muscle cell apoptotic process	GO:0010667	9.63	MIR21 MIR145 MIR106B
20	positive regulation of miRNA maturation	GO:1903800	9.61	TP53 EGFR
21	negative regulation of mitotic cell cycle	GO:0045930	9.61	TP53 MIR21 BCL2
22	aorta smooth muscle tissue morphogenesis	GO:0060414	9.57	MIR145 MIR143
23	positive regulation of vascular associated smooth muscle cell migration	GO:1904754	9.56	TERT MIR21 MIR143
24	regulation of phenotypic switching	GO:1900239	9.37	MIR145 MIR143
25	positive regulation of cellular response to hypoxia	GO:1900039	9.32	MIR21 MIR145
26	establishment or maintenance of cell type involved in phenotypic switching	GO:0044663	9.16	MIR145 MIR143
27	miRNA-mediated gene silencing by inhibition of translation	GO:0035278	9.02	MIR31 MIR21 MIR148A MIR145 MIR106B

Molecular functions related to Larynx Cancer according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	glutathione transferase activity	GO:0004364	9.63	GSTM1 GSTM3 GSTP1
2	mRNA 3'-UTR binding	GO:0003730	9.61	TP53 MIR486-1 MIR31 MIR21 MIR145 MIR143
3	mRNA base-pairing translational repressor activity	GO:1903231	9.23	MIR486-1 MIR31 MIR21 MIR148A MIR145 MIR143